Last reviewed · How we verify
Increasing the Dispersion and Absorption of Other Injected Drugs — Treatment Landscape & Competitive Intelligence
1 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Recombinant antithrombin (rhAT) | Recombinant antithrombin (rhAT) | Mayo Clinic | Dispersion agent; enzyme | Hyaluronic acid and connective tissue polysaccharides |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Mayo Clinic · 1 drug in Increasing the Dispersion and Absorption of Other Injected Drugs
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Increasing the Dispersion and Absorption of Other Injected Drugs:
- Increasing the Dispersion and Absorption of Other Injected Drugs treatment updates — RSS
- Increasing the Dispersion and Absorption of Other Injected Drugs treatment updates — Atom
- Increasing the Dispersion and Absorption of Other Injected Drugs treatment updates — JSON
Cite this brief
Drug Landscape (2026). Increasing the Dispersion and Absorption of Other Injected Drugs — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/increasing-the-dispersion-and-absorption-of-other-injected-drugs. Accessed 2026-06-10.
Related
- Increasing the Dispersion and Absorption of Other Injected Drugs full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing